{"abstract": "Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up.", "web_url": "https://www.nytimes.com/2016/09/27/business/dealbook/pfizer-remains-whole-but-the-option-to-split-could-return.html", "snippet": "Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up.", "lead_paragraph": "Pfizer has finally admitted that there is no rabbit in its breakup hat.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-jumbo.jpg", "height": 682, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Remains Whole, but the Option to Split Could Return", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 4, "major": "N"}], "pub_date": "2016-09-26T17:44:24+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/598f42d1-4e8a-56c9-9783-fba1887a4624", "word_count": 396, "uri": "nyt://article/598f42d1-4e8a-56c9-9783-fba1887a4624"}